Mehmet Fatih Akdoğan1, Alper Azak2, Nazım Denizli3, Bülent Huddam2, Gülay Koçak2, Murat Gücün3, Mustafa Adem Tatlısu4, Recep Demirci3, Bilal Yılmaz3, Mehmet Dikeç3, Murat Bakırtaş5, İbrahim Akdağ2, Murat Duranay2. 1. a Department of Internal Medicine , Haydarpaşa Numune Education and Research Hospital , Istanbul , Turkey . 2. b Department of Nephrology , Ankara Education and Research Hospital , Ankara , Turkey . 3. c Department of Nephrology , Haydarpaşa Numune Education and Research Hospital , Istanbul , Turkey . 4. d Department of Cardiology , Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Center , Istanbul , Turkey , and. 5. e Department of Biochemistry , Haydarpaşa Numune Education and Research Hospital , Istanbul , Turkey.
Abstract
PURPOSE: Patients diagnosed with chronic kidney disease (CKD) have a greater rate of cardiovascular mortality when compared with the general population. The soluble form of TNF-like weak inducer of apoptosis (TWEAK) and monocyte chemoattractan protein 1 (MCP-1) play important roles in cellular proliferation, migration and apoptosis. The current study aimed to analyze whether soluble TWEAK (sTWEAK) and MCP-1 levels are associated with the severity of coronary arterial disease (CAD) in CKD patients. METHODS: Ninety-seven patients diagnosed with CKD stages 2-3 according to their estimated glomerular filtration rate and the presence of kidney injury were included in the study. Plasma sTWEAK and MCP-1 concentrations were determined using commercially available ELISA kits. Coronary angiographies were performed through femoral artery access using the Judkins technique. RESULTS: Correlation analysis of sTWEAK and Gensini scores showed significant association (p < 0.01, r(2) = 0.287). Also significant correlation has been found in MCP-1 levels and Gensini scores (p < 0.01, r(2) = 0.414). When patients were divided into two groups with a limit of 17 according to their Gensini score, sTWEAK levels indicated a statistically significant difference (p < 0.01). CONCLUSIONS: Our findings support a relationship between sTWEAK and MCP-1 levels and CAD in CKD stages 2-3 patients.
PURPOSE:Patients diagnosed with chronic kidney disease (CKD) have a greater rate of cardiovascular mortality when compared with the general population. The soluble form of TNF-like weak inducer of apoptosis (TWEAK) and monocyte chemoattractan protein 1 (MCP-1) play important roles in cellular proliferation, migration and apoptosis. The current study aimed to analyze whether soluble TWEAK (sTWEAK) and MCP-1 levels are associated with the severity of coronary arterial disease (CAD) in CKDpatients. METHODS: Ninety-seven patients diagnosed with CKD stages 2-3 according to their estimated glomerular filtration rate and the presence of kidney injury were included in the study. Plasma sTWEAK and MCP-1 concentrations were determined using commercially available ELISA kits. Coronary angiographies were performed through femoral artery access using the Judkins technique. RESULTS: Correlation analysis of sTWEAK and Gensini scores showed significant association (p < 0.01, r(2) = 0.287). Also significant correlation has been found in MCP-1 levels and Gensini scores (p < 0.01, r(2) = 0.414). When patients were divided into two groups with a limit of 17 according to their Gensini score, sTWEAK levels indicated a statistically significant difference (p < 0.01). CONCLUSIONS: Our findings support a relationship between sTWEAK and MCP-1 levels and CAD in CKD stages 2-3 patients.
Authors: Matthew J Yousefzadeh; Marissa J Schafer; Nicole Noren Hooten; Elizabeth J Atkinson; Michele K Evans; Darren J Baker; Ellen K Quarles; Paul D Robbins; Warren C Ladiges; Nathan K LeBrasseur; Laura J Niedernhofer Journal: Aging Cell Date: 2017-12-31 Impact factor: 9.304